心脏应激与炎症标志物对2型糖尿病患者心力衰竭的预测:ADVANCE试验
在ADVANCE试验的3,098例2型糖尿病患者中开展巢式病例队列研究,评估NT-proBNP、hs-cTnT、IL-6和hs-CRP对心力衰竭发生或进展的预测价值。结果显示仅NT-proBNP在常规危险因素基础上持续且显著改善预测(C统计量0.8162升至0.8800),其余标志物联合或单独加入均未一致改善预测指标。
要点
- NT-proBNP每升高1个标准差,心衰发生或进展风险HR为3.06(95%CI 2.37, 3.96)。
- 将NT-proBNP加入常规危险因素模型后,5年风险预测C统计量由0.8162升至0.8800。
- hs-cTnT、IL-6或hs-CRP联合或加入NT-proBNP后均未一致改善预测指标。
核心结论
- 仅NT-proBNP在广泛临床危险因素和生物标志物之外,强烈且持续地改善2型糖尿病患者的心力衰竭预测。
研究设计与样本
- 在ADVANCE试验的3,098例2型糖尿病患者中开展巢式病例队列研究。
主要发现
- 校正主要危险因素后,各生物标志物升高均与心衰发生或进展风险升高显著相关。
- NT-proBNP每升高1个标准差,心衰发生或进展的HR为3.06(95%CI 2.37, 3.96)。
- hs-cTnT每升高1个标准差,HR为1.50(95%CI 1.27, 1.77)。
- IL-6每升高1个标准差,HR为1.48(95%CI 1.27, 1.72)。
- hs-CRP每升高1个标准差,HR为1.32(95%CI 1.12, 1.55)。
关键数值与推荐
- 将NT-proBNP加入含常规危险因素的模型后,5年风险预测C统计量由0.8162升至0.8800。
- 连续净重分类改善(NRI)为73.1%。
- 分类NRI(5年风险<5%、5-10%、>10%)为24.2%。
- hs-cTnT、IL-6或hs-CRP联合或加入NT-proBNP后,均未一致改善预测指标。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study examined the individual and combined effect of N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT), interleukin-6 (IL-6), and hs-CRP on the prediction of heart failure incidence or progression in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: A nested case-cohort study was conducted in 3,098 participants with type 2 diabetes in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. RESULTS: A higher value of each biomarker was significantly associated with a higher risk of heart failure incidence or progression, after adjustment for major risk factors. The hazard ratios per 1-SD increase were 3.06 (95% CI 2.37, 3.96) for NT-proBNP, 1.50 (1.27, 1.77) for hs-cTnT, 1.48 (1.27, 1.72) for IL-6, and 1.32 (1.12, 1.55) for hs-CRP. The addition of NT-proBNP to the model including conventional risk factors meaningfully improved 5-year risk-predictive performance (C statistic 0.8162 to 0.8800; continuous net reclassification improvement [NRI] 73.1%; categorical NRI [<5%, 5-10%, >10% 5-year risk] 24.2%). In contrast, the addition of hs-cTnT, IL-6, or hs-CRP did not improve the prediction metrics consistently in combination or when added to NT-proBNP. CONCLUSIONS: Only NT-proBNP strongly and consistently improved the prediction of heart failure in patients with type 2 diabetes beyond a wide range of clinical risk factors and biomarkers.
引用
- Ohkuma T, Jun M, Woodward M, et al. Cardiac Stress and Inflammatory Markers as Predictors of Heart Failure in Patients With Type 2 Diabetes: The ADVANCE Trial. Diabetes Care. 2017. PMID: 28684396. doi:10.2337/dc17-0509
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。